Document is current
Any future updates will be listed below
-
Authors
Tena-Chaves, David https://orcid.org/0009-0005-9175-8144
Pontes-Gomes, Inês
Palomeque, José Ángel
Toh, Eric
Baryalai, Palwasha
Kadler, Gabor https://orcid.org/0000-0001-8159-8945
Schuepbach, Reto A.
Heuberger, Dorothea M. https://orcid.org/0000-0002-8513-3528
Hurtado, Antoni https://orcid.org/0000-0002-0145-4763
Wai, Sun Nyunt https://orcid.org/0000-0003-4793-4671
- License Information
-
More Information
Article History
Received: 1 December 2024
Revised: 7 July 2025
Accepted: 11 August 2025
First Online: 28 August 2025
Competing interests
: AH provides advice to Novartis (clinical trial NeoLetTrib) and receives funding from Menarini pharma company. The other authors declare that there are no conflicts of interest.
: We clarify that all experiments were conducted entirely in vitro. All methods were performed in accordance with the relevant guidelines and regulations. The study did not involve human participants, identifiable data or images, patient samples, volunteer-based research, or studies involving live vertebrates. No clinical or drug trials were conducted. Therefore, ethics approval and informed consent requirements do not apply.
